Document Detail


Improving prevention and treatment of venous thromboembolism: clinical trial results.
MedLine Citation:
PMID:  22372589     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Background: Venous thromboembolism (VTE) incurs considerable socioeconomic costs, partly owing to the fact that the treatment and prevention of VTE via effective thromboprophylaxis remains suboptimal in the inpatient and outpatient settings of many healthcare systems. A number of organizations-including the National Quality Forum, The Joint Commission, and the Centers for Medicare and Medicaid Services-have established measures to assess and reduce the healthcare burden of VTE. These improvement strategies focus on increasing the use of thromboprophylaxis, implementing existing guidelines, and improving awareness. Findings: Based on clinical trial results, the oral anti-coagulants rivaroxaban, apixaban, and dabigatran etexilate have been approved in many countries for the prevention of VTE in patients after elective hip or knee replacement surgery. Recently, dabigatran etexilate and rivaroxaban have also been approved in the US for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. In addition, rivaroxaban is currently the only newer anti-coagulant that has been approved in Europe for the treatment of deep vein thrombosis and for the long-term prevention of recurrent VTE. These oral anti-coagulants have several advantages over established anti-coagulants, including no need for routine coagulation monitoring and only minimal food and drug interactions. These characteristics, together with convenient oral administration, may improve adherence and quality of life for patients, which could result in reductions in the rate of VTE. Conclusions: These three oral agents have several advantages over established anti-coagulants and could, therefore, address the unmet needs of patients, physicians, and healthcare systems, with the potential to reduce the burden of anti-coagulant management and the occurrence of VTE.
Authors:
Charles Mahan; Alex C Spyropoulos
Related Documents :
17258029 - Recombinant activated factor vii in cardiac surgery: a systematic review.
12615829 - Economic evaluation of three surgical interventions for menorrhagia.
18521509 - Cost and outcome: comparisons of two alternative bypassing agents for persons with haem...
16148549 - Infliximab use in crohn's disease: impact on health care resources in the uk.
15906909 - The clinical value of parenteral immunonutrition in surgical patients.
2111109 - Efficient management of diarrhea in the acquired immunodeficiency syndrome (aids). a me...
8913659 - Methotrexate in primary sjögren's syndrome.
2339919 - Experience with selective operative and nonoperative treatment of splenic injuries in 1...
15798409 - Ureteroscopy in the management of pediatric urinary tract calculi.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-28
Journal Detail:
Title:  Journal of medical economics     Volume:  -     ISSN:  1941-837X     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9892255     Medline TA:  J Med Econ     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Outcomes Research, New Mexico Heart Institute, University of New Mexico , Albuquerque, NM , USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Medical Responsibility in the Operating Room: The Example of an Amniotic Fluid Embolism.
Next Document:  Sociocultural input facilitates children's developing understanding of extraordinary minds.